Companies Combine to Form Ion Channel Consortium
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Together, the three companies will offer value added identification and validation of ion channel modulators. The Ion Channel Consortium combines Alion’s proprietary method for short-listing drug candidates, Specs’ reliable sourcing and synthesis of compounds, and Aurora’s patch clamp services.
Researchers now have an option that enables time and cost savings while providing a unique method to identify new drug candidates for channelopathies.
